18,803 results match your criteria Oncology[Journal]


Immunotherapy Advances in Urothelial Carcinoma.

Curr Treat Options Oncol 2018 Dec 15;19(12):79. Epub 2018 Dec 15.

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.

Opinion Statement: Checkpoint inhibitors have monumentally transformed the treatment of metastatic urothelial carcinoma. While the efficacy and safety of the different agents are similar in platinum-refractory metastatic urothelial carcinoma, pembrolizumab is the only agent that was superior to chemotherapy in a randomized phase III trial. Pembrolizumab and atezolizumab are also approved as first-line therapies in cisplatin-ineligible metastatic urothelial carcinoma. Read More

View Article
December 2018
1 Read

Making the Best of Available Options for Optimal Sarcoma Treatment.

Authors:
Axel Le Cesne

Oncology 2018 14;95 Suppl 1:11-20. Epub 2018 Dec 14.

For 35 years options for treating advanced soft tissue sarcoma (STS) were limited to doxorubicin, dacarbazine and ifosfamide. In 2007, trabectedin was approved. Since then, several other agents have become available and many more are in development, ushering in a new era in disease management. Read More

View Article
December 2018

Advancing towards Better Cooperation for Better Sarcoma Prognoses.

Oncology 2018 14;95 Suppl 1:5-10. Epub 2018 Dec 14.

Multidisciplinary teams (MDTs) are necessary to deliver the best sarcoma care. Planning the optimal therapeutic strategy per patient requires input and expertise from several disciplines. Case/cohort studies have reported improved patient outcomes associated with treatment by MDTs and/or treatment in sarcoma centres. Read More

View Article
December 2018

Prelims.

Authors:

Oncology 2018 14;95 Suppl 1:I-III. Epub 2018 Dec 14.

View Article
December 2018

Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study.

Lancet Oncol 2018 Dec 10. Epub 2018 Dec 10.

Department of Population Health, London School of Hygiene & Tropical Medicine, London, UK.

Background: Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival.

Methods: In this population-based study, we collected data from all patients aged 18-99 years diagnosed with primary, invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, from national colorectal cancer registries. Read More

View Article
December 2018

The importance of surgery in colorectal cancer treatment.

Authors:
Eva Angenete

Lancet Oncol 2018 Dec 10. Epub 2018 Dec 10.

Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital/Östra, Scandinavian Surgical Outcomes Research Group, 413 45 Gothenburg, Sweden. Electronic address:

View Article
December 2018

Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?

Authors:
Antoine Italiano

Curr Treat Options Oncol 2018 Dec 7;19(12):78. Epub 2018 Dec 7.

Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, 33076, Bordeaux, France.

Opinion Statement: Soft-tissue sarcomas represent a heterogeneous group of diseases accounting for up to 1% of cancer in adults and 15% of cancer in children. Introduction of next-generation sequencing (NGS) technologies has allowed to gain additional insight into the genetic diversity and complexity of sarcomas, including the potential therapeutic implications of some genetic alterations.Two large studies have investigated the role of targeted NGS to identify actionable mutations in patients with soft-tissue sarcomas. Read More

View Article
December 2018

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol 2018 Nov 30. Epub 2018 Nov 30.

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.

Background: Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma.

Methods: iLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and community hospitals in Australia, Canada, Israel, New Zealand, Russia, Turkey, the EU, and the USA in patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma, either aged 65 years or older or younger than 65 years with coexisting conditions. Read More

View Article
November 2018

Drug development for glioma: are we repeating the same mistakes?

Authors:
Roger Stupp

Lancet Oncol 2018 Dec 3. Epub 2018 Dec 3.

Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA. Electronic address:

View Article
December 2018
3 Reads

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.

Lancet Oncol 2018 Dec 3. Epub 2018 Dec 3.

Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Electronic address:

Background: Glioblastoma is a highly vascularised tumour and there are few treatment options after disease recurrence. Regorafenib is an oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases. We aimed to assess the efficacy and safety of regorafenib in the treatment of recurrent glioblastoma. Read More

View Article
December 2018

Ibrutinib: searching for a partner drug.

Lancet Oncol 2018 Nov 30. Epub 2018 Nov 30.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article
November 2018

CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer.

Oncology 2018 Dec 12:1-8. Epub 2018 Dec 12.

Department of Oncology, National Taiwan University Hospital, Taipei City,

Objective: We aimed to study the prognostic role of CpG island methylator phenotype (CIMP) in patients with different stages of colorectal cancer (CRC).

Material And Methods: We analyzed CIMP in stage I-IV CRC specimens from patients who were diagnosed between 2005 and 2013. CIMP status was determined using a 5-gene MethyLight-based assay. Read More

View Article
December 2018

Electronic Patient-Reported Outcomes: A New Standard of Care?

Oncology 2018 Dec 12:1-2. Epub 2018 Dec 12.

Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen,

View Article
December 2018

Expression Levels of microRNAs miR-93 and miR-200a in Pancreatic Adenocarcinoma with Special Reference to Differentiation and Relapse-Free Survival.

Oncology 2018 Dec 11:1-7. Epub 2018 Dec 11.

Department of Pathology, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.

Objectives: Protein levels of the transcription factor nuclear factor erythroid-derived 2-like 2 (Nrf2) and its inhibitor Kelch-like ECH-associated protein 1 (Keap1) have been proposed as prognostic factors in pancreatic ductal adenocarcinomas (PDACs). These cellular redox-state-regulating enzymes are targeted by several microRNAs, including miR-93 and miR-200a.

Methods: We assessed mRNA levels of Nrf2 and Keap1 and tissue expression of miR-93 and miR-200a in 51 patients with surgically treated PDAC. Read More

View Article
December 2018
1 Read

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Curr Treat Options Oncol 2018 Nov 15;19(12). Epub 2018 Nov 15.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Herman Pressler Dr. CPB 6.3279, Houston, TX, 77030, USA.

Opinion Statement: Use of poly(ADP-ribose) polymerase (PARP) inhibitors has greatly increased over the past 5 years. With several new Food and Drug Administration (FDA) approvals, three PARP inhibitors have entered into standard of care treatment for epithelial ovarian cancer (including ovarian, fallopian tube, and primary peritoneal cancer). Olaparib and rucaparib currently have indications for treatment of recurrent BRCA mutant ovarian cancer. Read More

View Article
November 2018

2018 American Society of Hematology Annual Meeting.

Authors:
Katherine Gourd

Lancet Oncol 2018 Dec 6. Epub 2018 Dec 6.

View Article
December 2018

Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer?

Lancet Oncol 2018 Oct 1;19(10):1285-1286. Epub 2018 Oct 1.

View Article
October 2018
24.690 Impact Factor

CD19-directed CAR T cells gain traction.

Lancet Oncol 2018 Nov 30. Epub 2018 Nov 30.

Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Perelman Center for Advanced Medicine, 34th and Civic Center Blvd, Philadelphia, PA 19104, USA. Electronic address:

View Article
November 2018
1 Read

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Lancet Oncol 2018 Nov 30. Epub 2018 Nov 30.

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study, with a median follow-up of 15·4 months (IQR 13·7-17·3), 89 (82%) of 108 assessable patients with refractory large B-cell lymphoma treated with axicabtagene ciloleucel achieved an objective response, and complete responses were noted in 63 (58%) patients. Here we report long-term activity and safety outcomes of the ZUMA-1 study. Read More

View Article
November 2018
1 Read
24.690 Impact Factor

Retrorectal tumour.

Authors:
Takeshi Kondo

Lancet Oncol 2018 Nov 1;19(11):e654. Epub 2018 Nov 1.

Department of General Medicine, Chiba University Hospital, Chiba City, Japan; Department of General Medicine, Kimitsu Chuo Hospital, Kisarazu, Japan. Electronic address:

View Article
November 2018

Correction to Lancet Oncol 2018; 19: 1480-92.

Authors:

Lancet Oncol 2018 Nov 1;19(11):e581. Epub 2018 Nov 1.

View Article
November 2018

Correction to Lancet Oncol 2016; 17: 164-73.

Authors:

Lancet Oncol 2018 Nov 1;19(11):e581. Epub 2018 Nov 1.

View Article
November 2018

Correction to Lancet Oncol 2018; 19: 1504-15.

Authors:

Lancet Oncol 2018 Nov 1;19(11):e581. Epub 2018 Nov 1.

View Article
November 2018

Correction to Lancet Oncol 2018; 19: 1192-204.

Authors:

Lancet Oncol 2018 Nov 1;19(11):e581. Epub 2018 Nov 1.

View Article
November 2018

Correction to Lancet Oncol 2018; 19: 1468-79.

Authors:

Lancet Oncol 2018 Nov 1;19(11):e581. Epub 2018 Nov 1.

View Article
November 2018

The silent victims of the US embargo against Iran.

Lancet Oncol 2018 Nov 1;19(11):e580. Epub 2018 Nov 1.

The Hospital for Sick Children, Toronto, ON, Canada.

View Article
November 2018

Quality of life after breast reconstruction-the BRIOS study.

Lancet Oncol 2018 Nov 1;19(11):e579. Epub 2018 Nov 1.

Kellogg College, Department of Continuing Education, University of Oxford, Oxford, UK; Department of Surgery and Cancer, Imperial College London, London, UK.

View Article
November 2018

Quality of life after breast reconstruction-the BRIOS study.

Lancet Oncol 2018 Nov 1;19(11):e578. Epub 2018 Nov 1.

G.Re.T.A. Group for Reconstructive and Therapeutic Advancements, Milan, Naples, Catania 95016, Italy.

View Article
November 2018

Quality of life after breast reconstruction-the BRIOS study.

Lancet Oncol 2018 Nov 1;19(11):e577. Epub 2018 Nov 1.

Linda McCartney Centre, Royal Liverpool and Broadgreen University Hospital, Prescot Street, Liverpool, UK.

View Article
November 2018

Monitoring asparaginase activity - Authors' reply.

Lancet Oncol 2018 Nov 1;19(11):e576. Epub 2018 Nov 1.

Department of Pediatrics, Universidade Federal do Rio Grande do Sul, Porto Alegre 2350, Brazil; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

View Article
November 2018

Monitoring asparaginase activity.

Lancet Oncol 2018 Nov 1;19(11):e575. Epub 2018 Nov 1.

Chief of Staff of the Secretary of Health Care, Ministry of Health, Brasilia, Brazil. Electronic address:

View Article
November 2018

Monitoring asparaginase activity.

Lancet Oncol 2018 Nov 1;19(11):e574. Epub 2018 Nov 1.

National Center for Bioimaging, Institute of Medical Biochemistry, Federal University of Rio de Janeiro-UFRJ, Brazil.

View Article
November 2018

Developing cancer care institutions for the developing world.

Lancet Oncol 2018 Nov 1;19(11):1436. Epub 2018 Nov 1.

Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK. Electronic address:

View Article
November 2018

A new perspective: from internal medicine resident to oncologist.

Lancet Oncol 2018 Nov 1;19(11):1433. Epub 2018 Nov 1.

Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.

View Article
November 2018

Lung squamous carcinoma involving the lip and cheek.

Lancet Oncol 2018 Dec;19(12):e726

Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China. Electronic address:

View Article
December 2018
2 Reads

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Lancet Oncol 2018 Dec;19(12):e720-e725

Department of Dermatology and Comprehensive Cancer Centre, University Hospital Essen, Essen, Germany.

It is important to differentiate between two concepts of adjuvant therapy in melanoma-what we have come to call late adjuvant and early adjuvant therapy. Early adjuvant therapy is defined as a medical intervention that is done after resection of a primary melanoma to eradicate possible undetectable minimal residual disease, whereas late adjuvant therapy is done when an overt metastatic disease (nodal or visceral) has been completely resected, to control disease better than if the same treatment were given at a later time, in the presence of multiple metastases. Early adjuvant therapy is thus a preventive treatment strategy, whereas late adjuvant therapy aims at anticipating treatment of metastatic disease. Read More

View Article
December 2018
2 Reads

Defining priority medical devices for cancer management: a WHO initiative.

Lancet Oncol 2018 Dec;19(12):e709-e719

Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, PA, USA.

Medical devices are indispensable for cancer management across the entire cancer care continuum, yet many existing medical interventions are not equally accessible to the global population, contributing to disparate mortality rates between countries with different income levels. Improved access to priority medical technologies is required to implement universal health coverage and deliver high-quality cancer care. However, the selection of appropriate medical devices at all income and hospital levels has been difficult because of the extremely large number of devices needed for the full spectrum of cancer care; the wide variety of options within the medical device sector, ranging from small inexpensive disposable devices to sophisticated diagnostic imaging and treatment units; and insufficient in-country expertise, in many countries, to prioritise cancer interventions and to determine associated technologies. Read More

View Article
December 2018
1 Read

Consensus on molecular imaging and theranostics in prostate cancer.

Lancet Oncol 2018 Dec;19(12):e696-e708

Department of Nuclear Medicine, Radboud University Medical Centre, Nijmegen, Netherlands; Department of Nuclear Medicine, The Institute of Cancer Research and The Royal Marsden National Health Service Foundation Trust, London, UK.

Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Read More

View Article
December 2018
3 Reads

Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer.

Lancet Oncol 2018 Dec;19(12):e683-e695

Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA. Electronic address:

Although muscle-invasive bladder cancer is commonly treated with radical cystectomy, a standard alternative is bladder preservation therapy, consisting of maximum transurethral bladder tumour resection followed by radiotherapy with concurrent chemotherapy. Although no successfully completed randomised comparisons are available, the two treatment paradigms seem to have similar long-term outcomes; however, clinicopathologic parameters can be insufficient to provide clear guidance in the selection of one treatment over the other. Recent advances in the molecular understanding of bladder cancer have led to the identification of new predictive biomarkers that ultimately might help guide the tailored selection of therapy on the basis of the intrinsic biology of the tumour. Read More

View Article
December 2018
1 Read

Correction to Lancet Oncol 2018; 19: 1480-92.

Authors:

Lancet Oncol 2018 Dec;19(12):e668

View Article
December 2018

Correction to Lancet Oncol 2018; 19: 1516-29.

Authors:

Lancet Oncol 2018 Dec;19(12):e668

View Article
December 2018

Correction to Lancet Oncol 2018; 19: 1437-48.

Authors:

Lancet Oncol 2018 Dec;19(12):e668

View Article
December 2018

Correction to Lancet Oncol 2017; 18: 1360-72.

Authors:

Lancet Oncol 2018 Dec;19(12):e667

View Article
December 2018

Correction to Lancet Oncol 2014; 15: 640-47.

Authors:

Lancet Oncol 2018 Dec;19(12):e667

View Article
December 2018

Correction to Lancet Oncol 2017; 18: 52-62.

Authors:

Lancet Oncol 2018 Dec;19(12):e667

View Article
December 2018

Correction to Lancet Oncol 2017; 18: 732-42.

Authors:

Lancet Oncol 2018 Dec;19(12):e667

View Article
December 2018

Correction to Lancet Oncol 2017; 18: e638.

Authors:

Lancet Oncol 2018 Dec;19(12):e667-e668

View Article
December 2018